[CNC] Centene: Q3 2026 Earnings Test Medicaid Rates Against Rising Acuity

Centene is the largest Medicaid and Marketplace health insurer in the United States and the largest stand-alone Medicare prescription drug plan (PDP) provider, covering medical costs for low-income and complex populations under contracts with state governments and federal health programs[1]. Third quarter 2026 (three months ended September 30, 2026) results are scheduled for 2026-10-27, according to the Drillr earnings calendar[2]. In the latest disclosed period, the second quarter of 2026, Centene's total revenues rose 10% to $53.579 billion, premium and service revenues rose 4% to $44.375 billion, the consolidated health benefits ratio (HBR) fell to 89.6% from 93.0% a year earlier, GAAP diluted EPS was $2.19 and adjusted diluted EPS was $2.51[3][4]. On July 28 the company raised its 2026 adjusted diluted EPS floor from greater than $4.40 to greater than $4.80 and its GAAP diluted EPS floor to greater than $3.11, guiding to total revenues of $193.5 billion to $197.5 billion and a full-year HBR of 90.5% to 91.3%[3][5]; management also said the third quarter would come in slightly above break-even and the fourth quarter would show a loss, and that about $0.50 of 2026 EPS comes from 2025 settlement items that will not recur in 2027[5]. Because first-quarter adjusted EPS was $3.37, first-half adjusted EPS totaled $5.88, so a full-year floor above $4.80 implies combined second-half EPS of no less than about -$1.08[6][3]. Analyst estimates compiled by Drillr on 2026-10-22 put third-quarter adjusted EPS at $0.10 (12 analysts, range $0.01 to $0.14), revenue at $47.12 billion (8 analysts) and full-year adjusted EPS at $4.87 (range $4.78 to $5.07); the revenue basis is unclear, because the comparable second-quarter revenue estimate was $47.64 billion while actual total revenues were $53.579 billion and premium and service revenues were $44.375 billion, and the second-quarter EPS estimate of $1.09 was far below the actual $2.51, so these figures should not be compared directly with reported revenue[7].

Three things matter most in Centene's Q3 2026 earnings. First, whether Medicaid rates are keeping pace with a changing population: the second-quarter Medicaid HBR was 93.9% against full-year guidance of about 93.5%, the expected full-year membership decline has widened from about 6% to 8%-9%, acuity among remaining members has risen slightly, and management is holding 50 basis points of rate benefit in reserve, so the third-quarter HBR will show whether that cushion is enough[5]. Second, whether the Marketplace margin recovery holds: the Commercial segment HBR fell to 79.2% in the second quarter from 90.6% a year earlier and full-year Marketplace pre-tax margin guidance rose from 3% to 4.5%-5%, but part of that recovery rests on a 2026 risk adjustment estimate that will keep moving with later Wakely data, and in 2025 a similar estimate collapsed mid-year and wiped out the year's profit[4][5][1]. Third, whether Medicare can get through the second-half drug-cost peak without a new premium deficiency reserve: as of June the company had recorded no premium deficiency reserve for the 2026 Medicare Advantage contract year and had raised PDP full-year pre-tax margin guidance to above 3%, but under the Inflation Reduction Act (IRA) cost structure the drug costs borne by plans concentrate in the second half, making the third quarter the first test of both assumptions[4][5].

Company Background and Business Structure

Centene is a managed care company built around government-funded populations, headquartered in St. Louis, Missouri[8], with Sarah M. London as chief executive. The remaining Magellan Health businesses, acquired in 2022, were placed under a definitive divestiture agreement in December 2025, which led to non-cash impairment charges of $513 million ($389 million after tax)[1]. The finance leadership is also changing: CFO Drew Asher will step down on December 31, 2026, and Chris Neczypor becomes CFO effective January 1, 2027[8].

The company reports four segments, Medicaid, Medicare, Commercial and Other, and the three risk-bearing segments generate almost all of its gross margin[1]. At the end of 2025, Medicaid served 12.5 million members in 30 states, with Florida and New York each contributing about 10% or more of Medicaid premiums; the Marketplace business, individual coverage sold under the Ambetter brand, served 5.5 million members in 29 states; Medicare Advantage served 1.0 million members in 32 states with one of the highest concentrations of dual-eligible (D-SNP) members among peers; and stand-alone PDP served 8.1 million members in all 50 states and the District of Columbia[1]. The mix shifted sharply in 2026: by June 30, Medicaid membership had fallen to 12,110,700 and Marketplace to 3,494,700, while PDP grew to 8,803,000[4]. Using 2025 segment revenues of $37.21 billion for Medicare, $42.003 billion for Commercial and $5.13 billion for Other, the remaining roughly $110.4 billion came from Medicaid, about 57% of consolidated total revenues of $194.777 billion[1].

Centene's revenue and cost structure makes it highly sensitive to government pricing. States pay a per-member-per-month premium and reset rates actuarially each year, CMS pays Medicare premiums based on bids and risk scores, Marketplace premiums are set in the summer before the plan year, and ACA risk adjustment moves money between insurers according to each plan's risk score relative to the state average[1]. Premium taxes collected on behalf of states are booked as revenue and then remitted, and state directed payments are pass-through in nature, so both inflate revenue with almost no profit; claims are paid weeks to months after care is delivered, and at June 30 medical claims liabilities were $20.3 billion with 47 days in claims payable[3]. PDP drug purchasing runs through the partnership with Express Scripts (ESI), and management said the business carries about $25 billion in annual premium revenue and more than $60 billion in annual pharmacy spend[5].

Financial History and Current Position

2025 was Centene's earnings trough: revenue kept growing, but medical costs and the risk adjustment write-down consumed profit. Total revenues for 2025 rose 19% to $194.777 billion and premium and service revenues rose 20% to $174.6 billion, yet the consolidated HBR climbed to 91.9% from 88.3% in 2024 and consolidated gross margin fell to $14.209 billion from $17.069 billion[1]. In July 2025 the company cut its expected 2025 Marketplace net risk adjustment transfer because of significantly higher estimated market morbidity, and in the third quarter it recorded a $6.7 billion goodwill impairment, ending the year with a GAAP diluted loss of $13.53 per share and adjusted diluted EPS of $2.08[1].

Segment gross margin for 2025 shows the pressure concentrated in Commercial and Medicaid. In 2025 Medicaid gross margin was $5.690 billion, Medicare $2.983 billion, Commercial $5.101 billion and Other $435 million; Commercial gross margin had been $7.663 billion in 2024 and Medicaid $6.246 billion[1]. The HBR increase was driven by lower Marketplace estimated risk adjustment revenue, higher Marketplace medical costs, IRA-related program changes in PDP, and higher Medicaid costs from behavioral health, home health and high-cost drugs, only partly offset by Medicaid rate increases[1]. Operating cash flow was $5.088 billion in 2025 against just $154 million in 2024; for the year, capital expenditures were $767 million, debt repayments and repurchases $1.895 billion and share repurchases $475 million, while the adjusted SG&A expense ratio fell to 7.4% from 8.5%[1].

Profit rebounded clearly in the first two quarters of 2026, but the rebound includes one-time items. In the first quarter, total revenues rose 7% to $49.9 billion, HBR was 87.3% (87.5% a year earlier), the adjusted SG&A expense ratio was 7.6%, GAAP diluted EPS was $3.11, adjusted diluted EPS was $3.37 and operating cash flow was $4.4 billion[9][6]. The second-quarter HBR of 89.6%, below 93.0% a year earlier, partly reflected favorable resolution of 2025 benefit-year programmatic elements in Medicare and the fact that a Medicare Advantage premium deficiency reserve was added in the 2025 quarter but none in 2026; the adjusted SG&A expense ratio was 6.9% (7.1% a year earlier)[3]. Favorable prior-year reserve development in the first half totaled $1.778 billion, including $1.0 billion in Medicaid, $251 million in Medicare and $509 million in Commercial, which also lowered reported HBR[4].

The balance sheet improved in the first half of 2026, but cash freely available to the parent remains limited. First-half operating cash flow was $7.956 billion versus $3.295 billion a year earlier; over the same period the company repaid and repurchased $1.304 billion of debt and bought back only $33 million of stock[3]. At June 30, cash, investments and restricted deposits totaled $44.8 billion, but only $715 million was available for general corporate use; in the second quarter the company repurchased $260 million of senior notes due 2027 and 2028, ending with total debt of $16.1 billion and no borrowings on its $4.0 billion revolving credit facility[3]. Debt to capitalization fell from 46.5% in the fourth quarter of 2025 to 43.2% in the first quarter of 2026, senior notes outstanding were $14.2 billion at June 30, and $1.8 billion remained under the share repurchase program[6][4].

Operating Model

Centene's revenue equals member months in each segment multiplied by per-member-per-month rates, plus service revenue and pass-through premium taxes. Medicaid rates are set actuarially by states, with the 2026 composite rate increase forecast at about 5% while membership is expected to fall 8%-9% for the year; Medicare revenue is paid by CMS based on bids and risk scores, with PDP membership growth lifting premiums; and Marketplace revenue combines member contributions and federal subsidies, moving up or down with ACA risk adjustment estimates[5][1]. In July the company raised total revenue guidance by $6.0 billion but premium and service revenue guidance by only $2.0 billion, to $173.0 billion to $177.0 billion, with the gap coming mainly from premium tax pass-through that barely affects profit[3].

The central profit variable is each segment's HBR, because every 1 percentage point change in consolidated HBR moves pre-tax profit by about $1.7 billion on roughly $173 billion of annual premiums[3]. Medicaid HBR is set by the race between state rates and member acuity, Marketplace HBR by pricing and risk adjustment, and Medicare HBR by bid assumptions and drug costs under the IRA; beyond that, 2026 guidance calls for an adjusted SG&A expense ratio of 6.9% to 7.5% and investment and other income of about $1.50 billion[3]. Seasonality front-loads profit: on the first-quarter call management explained that Medicaid HBR runs above the annual average in the second and third quarters, Marketplace HBR slopes steadily higher, and Medicare HBR rises each quarter because of the PDP mix, which is why the third quarter lands around break-even and the fourth quarter shows a loss[10].

Cash flow benefits from collecting premiums before paying claims, but most of the cash sits inside regulated insurance subsidiaries. With stable membership, roughly 47 days in claims payable keep operating cash flow positive; however, the timing of risk adjustment receivables and payables, state directed payments and drug rebates creates large swings between quarters, and second-quarter operating cash flow of $3.6 billion was held back by the net improvement in the 2025 risk adjustment transfer position[3]. The parent relies on subsidiary dividends to service debt and buy back stock: in 2025 it received $1.671 billion in dividends from subsidiaries while contributing $2.001 billion of capital to them, which means any rise in subsidiary capital requirements squeezes the cash the parent can use for debt service and buybacks[1].

Industry and Competitive Position

Centene's scale advantage is concentrated in government-funded populations: based on the most recent public membership data, it is the nation's largest Medicaid and Marketplace insurer and the largest stand-alone PDP provider[1]. Its main competitors include national managed care companies such as Elevance, UnitedHealth, Molina and CVS/Aetna; Medicaid contracts are won through state procurements, and competition turns on network size and quality, benefit design and service. Scale brings a low administrative cost ratio, with an adjusted SG&A expense ratio of just 6.9% in the second quarter of 2026, but the company is highly sensitive to state rates and federal policy[3].

Policy is the biggest constraint on Centene's competitive position, and its effects concentrate after 2027. The One Big Beautiful Bill Act (OBBBA), passed in July 2025, requires work or community engagement for the expansion population and more frequent eligibility redeterminations, which could raise morbidity in the Medicaid expansion population largely beginning in 2027; adjustments to provider taxes and state directed payments beginning in 2028 could also reduce federal Medicaid funding[1]. In addition, California will move its Medi-Cal Unsatisfactory Immigration Status (UIS) population from managed care to fee-for-service on January 1, 2027, and the expiration of enhanced advance premium tax credits (APTCs) together with a new final rule raised overall Marketplace morbidity[4]. In Medicare Advantage, about 60% of the company's members are in plans rated 3.5 stars or higher, including about 20% in 4-star plans[4].

Core Debates

With Medicaid membership set to fall 8%-9% this year and the remaining members sicker, is Centene's roughly 5% rate increase enough to hold its Medicaid benefit ratio near 93.5%?

This question matters because Medicaid accounts for more than half of Centene's total revenue, and one premise of full-year EPS guidance is that its HBR stays near 93.5%[1][5]. Medicaid gross margin fell from $6.246 billion in 2024 to $5.690 billion in 2025, and rising behavioral health, home health and high-cost drug costs were among the reasons consolidated HBR climbed from 88.3% to 91.9%[1]. From 2027, OBBBA work requirements and more frequent redeterminations will keep reshaping the member mix, so the relationship between rates and costs in the second half of 2026 is the baseline for judging whether this business can stabilize before the policy shock.

Current evidence shows rates running ahead of costs for now, but the population is changing faster. First-quarter Medicaid HBR was 93.1%, a 50 basis point improvement from a year earlier, and second-quarter HBR was 93.9%, in line with forecasts, leaving the first half at about 93.5%, right on full-year guidance[10][5]. The July rate cycle came in better than expected, lifting the full-year composite rate forecast from 4.5% to about 5% against an underlying cost trend still in the mid-4% range; yet membership at June 30 was 12,110,700, down 3.3% from 12,518,400 at the end of 2025, the expected full-year decline widened from about 6% to 8%-9%, attrition was concentrated in the expansion population, management said overall acuity had ticked up slightly, and it is holding 50 basis points of rate benefit in reserve[4][5]. Medicaid also had $1.0 billion of favorable prior-year reserve development in the first half, which helped reported HBR; that supports an alternative reading in which first-half stability came from a moderate flu season and reserve releases, and in which the rising cost of the remaining population shows up before rates catch up once attrition accelerates in the second half[4][6].

The financial transmission for this debate is direct. States reset rates in January and July, and the 2026 composite increase of about 5% sits above the mid-4% underlying cost trend; at the same time, redeterminations and pre-OBBBA verification drive attrition in the expansion population and raise acuity among those who remain[5]. If per-member-per-month costs rise faster than rates, Medicaid HBR goes up and segment gross margin falls; if rates stay ahead of the cost trend, HBR improves and gross margin rises. The numeric baselines are second-quarter Medicaid segment gross margin of $1.388 billion, against $1.117 billion a year earlier and $1.618 billion in the first quarter[4][9]; on roughly $22.7 billion of second-quarter Medicaid premiums, each 1 percentage point of higher HBR cuts quarterly gross margin by about $230 million[4].

What remains unresolved is how far acuity rises and how fast rates catch up. In the third quarter, the signals are whether Medicaid HBR comes in no higher than the second quarter's 93.9% and full-year guidance of about 93.5% holds, how membership at September 30 compares with the 8%-9% full-year decline and how management describes acuity, and whether the 50 basis point rate reserve is used and how 2027 rate discussions handle OBBBA-related adjustments[5]. A third-quarter Medicaid HBR above 94.2% or a higher full-year HBR outlook would show rates failing to keep up with acuity; a flat or lower HBR with membership declines within guidance would support the view that rates are leading the cost trend.

Ambetter shed about 40% of its members and margins recovered to a 4.5%-5% outlook; is that pricing working, or a risk-adjustment estimate that is optimistic for now?

The Marketplace was where Centene's 2025 profit collapse began, so the quality of its recovery directly determines how credible 2026 guidance is. After the mid-2025 drop in the risk adjustment estimate, Commercial segment gross margin fell from $7.663 billion in 2024 to $5.101 billion in 2025, and the company recorded a $6.7 billion goodwill impairment in the third quarter[1]. In the second quarter of 2026, Commercial gross margin was $1.947 billion, double the $946 million of a year earlier, and it was one of the main sources of the increase in full-year adjusted EPS guidance to above $4.80[4][5].

The recovery came first from broad repricing and second from risk adjustment settlements and estimates. Because the expiration of enhanced APTCs and the final rule raised the baseline of market morbidity, the company took corrective pricing actions covering 95% of Marketplace membership, and members fell from 5,541,400 at the end of 2025 to 3,494,700 at June 30[4]. Second-quarter Commercial HBR was 79.2%, versus 90.6% a year earlier and about 75.3% in the first quarter; management attributed the improvement to a favorable final 2025 risk adjustment reconciliation of about $180 million, data showing the company's 2026 relative risk position was better than earlier guidance assumed, and moderating medical trend[5][9]. On the 10-Q basis, final 2025 risk adjustment results produced a $481 million pre-tax benefit after offsetting increases in the Minimum Medical Loss Ratio (MLR) payable, the Risk Adjustment Data Validation (RADV) accrual and other offsets, a different scope from the roughly $180 million cited on the call, and the two figures cannot be fully reconciled[4]. The alternative reading is that the 2026 risk adjustment receivable is still an estimate based on the first round of Wakely industry data, and that a similar estimate was cut sharply in mid-2025[4][1].

The transmission runs from market morbidity to the risk adjustment receivable and then to Commercial HBR. The expiration of enhanced APTCs and the new rule raised overall market morbidity, the company repriced and its membership shrank, and the silver-tier members who remain are sicker; but risk adjustment transfers money to the company according to relative risk scores, so if its risk score stays high relative to the state average, premiums plus the risk adjustment receivable cover medical costs, keeping Commercial HBR low and gross margin high[4][1]. If later Wakely data show industry morbidity rising just as much, the company's relative risk advantage narrows, the receivable is cut and HBR rises; the numeric baselines are second-quarter Commercial gross margin of $1.947 billion ($2.358 billion in the first quarter) and full-year Marketplace pre-tax margin guidance of 4.5%-5%[4][9][5].

What remains unresolved is how the 2026 risk adjustment estimate will change as Wakely data arrive through 2026 and 2027[4]. In the third quarter, the signals are whether Commercial HBR rises steadily with seasonality rather than jumping to roughly 84% or higher, whether management keeps the 4.5%-5% pre-tax margin guidance and how it describes later Wakely data, and Marketplace membership at September 30 along with the effect of program integrity reviews. A negative revision to the risk adjustment receivable or a cut to margin guidance would show the recovery leaned on an optimistic estimate; unchanged margin guidance with a stable HBR would support a recovery driven by pricing and risk position.

With PDP margins just raised above 3% and Medicare Advantage near breakeven, can Medicare get through the second-half drug-cost peak without a new premium deficiency reserve?

Medicare is the main seasonal source of Centene's expected fourth-quarter loss and was one of the reasons HBR rose in 2025, so its second-half cost path decides whether full-year guidance holds. Centene is the largest stand-alone PDP provider in the United States, with about $25 billion in annual PDP premium revenue and more than $60 billion in annual pharmacy spend[1][5]. IRA reforms raised PDP costs in 2025; Medicare gross margin for all of 2025 was $2.983 billion, while first-half 2026 already reached $2.719 billion ($1.554 billion in the first quarter and $1.165 billion in the second)[1][9][4].

Both Medicare businesses beat expectations in the first half, but one-time items played a part. Medicare HBR was 84.9% in the first quarter and 89.5% in the second, the latter including one-time favorable 2025 settlements; recalculated from 10-Q segment data, the second quarter of 2025 was about 90.9%[10][5][4]. Because specialty drug trend came in below original expectations, the company raised PDP full-year pre-tax margin guidance from 2% to above 3%; Medicare Advantage, just over 40% of segment revenue, is approaching full-year break-even, and as of June no premium deficiency reserve had been recorded for the 2026 contract year, whereas the reserve was increased in the comparable 2025 period[5][4][3]. The alternative reading is that part of the first-half outperformance came from one-time settlements and part from costs shifting later in the year under the IRA; on the first-quarter call management already explained that Medicare HBR rises each quarter because of the PDP mix, and the outperformance could fade as costs concentrate in the second half[10].

The transmission for this debate starts with the 2026 bids. The company raised PDP premiums and narrowed its MA footprint in its bids, PDP membership grew from 8,118,600 at the end of 2025 to 8,803,000 at June 30 with higher premium per member, and MA concentrated on dual-eligible members[4][3]. The IRA's cap on member out-of-pocket costs shifts more drug cost onto plans in the second half, so Medicare HBR climbs each quarter; if specialty drug trend and MA utilization stay below bid assumptions, the second-half HBR rise stays limited and Medicare gross margin and PDP margins hold, otherwise the company has to record a premium deficiency reserve or cut margins. On about $25 billion of annual PDP premiums, each 1 percentage point drop in pre-tax margin reduces profit by about $250 million[5].

What remains unresolved is the actual size of the second-half drug-cost peak. In the third quarter, the signals are whether the company records a premium deficiency reserve for the 2026 MA contract year, whether PDP full-year pre-tax margin guidance above 3% holds and how management describes specialty drug trend, and whether changes in Medicare segment gross margin and HBR can be explained by IRA seasonality[5]. Recording an MA premium deficiency reserve or cutting PDP margins would show second-half costs running above bid assumptions; no reserve and unchanged PDP guidance would support a durable Medicare profit improvement.

Risks and Falsifiers

The first risk is the stacking of 2027 policy changes: OBBBA work requirements and more frequent redeterminations mainly affect the expansion population, about 18% of the Medicaid portfolio, provider tax and state directed payment adjustments follow from 2028, and California's UIS population moves to fee-for-service, which together could shrink membership, raise acuity and tighten state budgets at the same time[1][4][5]. The exposed financial line is Medicaid, about 57% of consolidated total revenues, and management expects Medicaid margin recovery to be held back in the second half of 2026 and part of 2027 before accelerating in the second half of 2027[1][5]. This risk would weaken if the third-quarter call confirms that states will use mid-year or retroactive rate adjustments to address acuity shifts and the preliminary 2027 framework shows Medicaid margins still improving.

The second risk is the one-time content of 2026 earnings combined with the finance leadership handover. 2026 adjusted EPS guidance is above $4.80, of which about $0.50 comes from 2025 settlement items that will not recur in 2027, and with the CFO handing over at the end of 2026, management's first statements about 2027 after the third quarter could differ from what analysts have assumed[5][8][7]. Drillr's compiled 2027 adjusted EPS estimate is $5.30 (12 analysts), an outside analyst figure rather than company guidance[7]. This risk would weaken if the preliminary 2027 framework given in the third or fourth quarter explicitly covers the one-time gap and the CFO transition comes without changes in accounting estimate methods.

The third risk is that Medicaid attrition concentrated in the expansion population raises the acuity of remaining members faster than rates catch up, pushing second-half HBR above the full-year assumption of about 93.5%[5]. On roughly $22.7 billion of second-quarter Medicaid premiums, each 1 percentage point of higher HBR cuts quarterly gross margin by about $230 million, and management is holding 50 basis points of incremental rate benefit in reserve against this[4][5]. The risk would not hold if third-quarter Medicaid HBR comes in no higher than the second quarter's 93.9%, full-year guidance of about 93.5% stands, and management has not used, or has released, the 50 basis point reserve.

The fourth risk is that later rounds of Wakely data or CMS program integrity reviews force a cut to the 2026 risk adjustment receivable, or that second-half attrition changes the member mix, repeating the mid-2025 collapse in the risk adjustment estimate[4][5]. The exposed financial line is Commercial segment gross margin: the second quarter's $1.947 billion includes one-time items such as the 2025 settlement, and the 2025 cut to the risk adjustment estimate took full-year Commercial gross margin from $7.663 billion to $5.101 billion[4][1]. This risk would weaken if management confirms in the third quarter that the 2026 risk adjustment estimate has not been cut and keeps full-year Marketplace pre-tax margin guidance at 4.5%-5%.

The fifth risk is that PDP specialty drug costs or MA utilization run above bid assumptions in the second half, forcing the company to record a new premium deficiency reserve for the 2026 MA contract year or to cut PDP margins[5][4]. The exposed financial line is Medicare segment gross margin: on about $25 billion of annual PDP premiums, each 1 percentage point drop in pre-tax margin costs about $250 million, against Medicare segment gross margin of $1.165 billion in the second quarter[5][4]. The risk would not hold if the third quarter brings no premium deficiency reserve for the 2026 MA contract year and PDP full-year pre-tax margin guidance stays above 3%.

What to Watch Next

• Medicaid rates versus acuity: second-quarter 2026 Medicaid HBR was 93.9% with full-year guidance near 93.5%[5]. A third-quarter reading above 94.2% or a higher full-year outlook would mean rates are lagging; flat or lower would support rates leading costs.
• Medicaid membership: 12,110,700 at June 30, 2026[4]. Watch September 30 membership against the 8%-9% full-year decline; a steeper drop with rising acuity would signal more pressure.
• The 50 basis point rate reserve, unused so far[5]. Drawing on it would mean acuity is running above assumptions; watch 2027 rate discussions too.
• Marketplace margin recovery: Commercial HBR was 79.2% in the second quarter[4]. A jump to roughly 84% or higher would point to an optimistic estimate.
• Marketplace pre-tax margin guidance of 4.5%-5% for 2026[5]. A cut, or a negative risk adjustment revision, would undercut the recovery.
• Medicare premium deficiency reserve for 2026 MA: none recorded as of June[4]. A third-quarter charge would show costs above bid assumptions.
• PDP pre-tax margin guidance above 3% for 2026[5]. A cut would indicate specialty drug costs rebounding.
• The 2027 framework: about $0.50 of 2026 guidance is one-time[5]. Coverage of that gap with continued Medicaid margin improvement would ease the risk.

Conclusion

Centene's profit depends on the HBR of three government-linked insurance segments, and its 2026 recovery rests on rates, risk adjustment estimates and bid assumptions at the same time. The company generated $194.777 billion of revenue in 2025 but posted a GAAP loss of $13.53 per share as HBR rose to 91.9% and it took a $6.7 billion goodwill impairment; in the first half of 2026, adjusted EPS totaled $5.88, operating cash flow reached $7.956 billion, total debt fell to $16.1 billion and full-year adjusted EPS guidance rose to above $4.80[1][6][3]. The central unresolved relationships are whether Medicaid's roughly 5% rate increase covers the rise in acuity from attrition, whether the 4.5%-5% Marketplace margin rests on a durable relative risk position, and whether Medicare can get through the second-half drug-cost peak without a new premium deficiency reserve[5].

There is a clear gap in outside views. From the July 28, 2026 second-quarter release to this report, the public material available consisted of results recaps, company announcements (including 2027 Marketplace and Medicare products, a Gold Card program and a note redemption) and a short balance-sheet commentary whose full text could not be read; broker views relayed secondhand could not be checked against their originals, so no independent outside interpretation is cited here and none of this material is treated as a market consensus. Readers can compare only the company's own guidance with the numeric estimates compiled by Drillr: the third-quarter adjusted EPS estimate of $0.10 points the same way as management's "slightly above break-even" remark, and the full-year estimate of $4.87 sits slightly above the $4.80 guidance floor[5][7].

What would most change the current understanding is a combination of observations rather than any single number. If third-quarter Medicaid HBR is no higher than 93.9%, Commercial HBR is stable with Marketplace margin guidance intact, Medicare records no new premium deficiency reserve, and the full-year adjusted EPS floor is kept or raised, the 2026 recovery looks more like the result of pricing and cost management; if Medicaid HBR breaks above 94.2%, the risk adjustment receivable is cut or MA records a new premium deficiency reserve, and the preliminary 2027 framework fails to cover the roughly $0.50 one-time gap and the membership changes from OBBBA, the current understanding of the recovery would be materially weakened[5][4].

Sources

[1] CNC FY2025 10-K filed 2026-02-17 · 2026-02-17 · 10-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001071739&type=10-K&dateb=&owner=include&count=40

[2] CNC earnings calendar updated 2026-10-22 · 2026-10-22 · Drillr earnings calendar

[3] CNC Q2 2026 8-K filed 2026-07-28 · 2026-07-28 · 8-K · https://www.sec.gov/Archives/edgar/data/0001071739/000107173926000154/a20260728ex991pressrelease.htm

[4] CNC Q2 2026 10-Q filed 2026-07-28 · 2026-07-28 · 10-Q · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001071739&type=10-Q&dateb=&owner=include&count=40

[5] CNC Q2 2026 earnings call 2026-07-28 · 2026-07-28 · earnings-call · https://investors.centene.com/

[6] CNC Q1 2026 8-K filed 2026-04-28 · 2026-04-28 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001071739&type=8-K&dateb=&owner=include&count=40

[7] Drillr analyst estimates CNC Q3 2026 retrieved 2026-10-22 · 2026-10-22 · Drillr analyst estimates · https://gateway.drillr.ai/mcp/private

[8] CNC CFO transition 8-K filed 2026-08-17 · 2026-08-17 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001071739&type=8-K&dateb=&owner=include&count=40

[9] CNC Q1 2026 10-Q filed 2026-04-28 · 2026-04-28 · 10-Q · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001071739&type=10-Q&dateb=&owner=include&count=40

[10] CNC Q1 2026 earnings call 2026-04-28 · 2026-04-28 · earnings-call · https://investors.centene.com/